Elekta stock holds steady as margins and turnaround plan stay in focus

Elekta stock (ISIN SE0000163628) has been trading at a relatively steady level on Nasdaq Stockholm in mid September 2026, with investors focusing less on short-term price swings and more on the company’s turnaround story and efforts to improve margins and cash generation as of September 20, 2026.

Margins remain central to Elekta’s turnaround

The Stockholm-based cancer care technology group has been working for several quarters to lift profitability in its core radiation therapy equipment and software business, with recent interim figures for its latest reported quarter showing revenue growth paired with ongoing pressure on operating margins compared with the prior year period, according to data summarized on investor portals in September 2026.

In the most recent fiscal year reported within the past two years, Elekta posted higher full-year revenue than the preceding year, but the operating margin remained in the single-digit range, underlining that the company still has some way to go before reaching the double-digit margin levels targeted in its strategic plan; historical context from the prior fiscal year shows that revenue increased by a mid-single-digit percentage while the margin only improved by around one percentage point year on year.

Order intake, cash flow and competitive landscape

Alongside margins, Elekta’s turnaround has also emphasized stabilizing order intake and strengthening free cash flow, with the latest quarterly report indicating that net sales in the most recently reported quarter grew versus the same period a year earlier and that cash flow before financing improved compared with the historical performance of the company in the fiscal year two years ago.

The company operates in a concentrated global market for radiation therapy and oncology software, where large projects, public tenders and hospital investments can cause volatility from quarter to quarter; in the last reported financial year, Elekta’s order bookings increased compared with the previous year, but delays in installations and supply chain constraints had an impact on revenue recognition and profitability, which is why management’s focus has shifted strongly toward execution, efficiency and service revenue.

Analyst focus on valuation and execution risk

Recent analyst commentary compiled on financial portals in September 2026 points out that Elekta’s valuation reflects both its solid installed base and recurring service revenues and the execution risk associated with delivering on its margin and cash flow targets, with some houses emphasizing that any disappointment versus guidance on operating margin or cash conversion could weigh on Elekta stock even if revenue growth remains intact.

Conversely, the same overviews show that analysts see scope for upside if Elekta can convert its strong pipeline of orders into higher-margin revenue and sustain double-digit growth in software and service offerings, since this would support a re-rating of the shares relative to peers in the broader medical technology sector and potentially narrow the valuation gap compared with competitors that already deliver higher operating margins and more robust free cash flow.

Stock trading and investor perspective

On Nasdaq Stockholm, Elekta stock continues to trade in Swedish krona at a level that is broadly in line with its quotations earlier in September 2026, leaving the shares neither near a 52-week high nor close to a 52-week low and underscoring the market’s wait-and-see stance on the company’s ability to expand margins and strengthen cash generation as of mid September 2026.

More news and analyses on Elekta stock